

I. AMENDMENTS

IN THE CLAIMS

Cancel claims 3-9, 11, and 20-26 without prejudice to renewal.

1. (Previously presented) A method of reducing goblet cell hyperplasia in an airway of an individual, comprising:

administering to a patient suffering from airway hypersecretion of mucus due to airway goblet cell hyperplasia an epidermal growth factor receptor (EGF-R) antagonist that binds the EGF-R in an amount effective to reduce goblet cell hyperplasia, wherein the EGF-R antagonist is a tyrosine kinase inhibitor selective for EGF-R.

2.-11. (Canceled)

12. (Original) The method of claim 1, wherein the antagonist is administered by injection.

13. (Original) The method of claim 12, wherein the antagonist is administered intravenously with a carrier in the form of normal saline solution.

14. (Original) The method of claim 1, wherein the antagonist is administered by inhalation.

15. (Original) The method of claim 1, wherein the antagonist is administered by liposome delivery.

16. (Original) The method of claim 15, wherein said liposome is sterically stabilized and administered intravenously.

17.-26. (Canceled)